Prihlásiť sa Zaregistrujte sa zadarmo

Cena / výnosy spoločnosti Kazia Therapeutics

Aká je hodnota metriky Cena / výnosy spoločnosti Kazia Therapeutics?

Hodnota metriky Cena / výnosy spoločnosti Kazia Therapeutics Limited je 1.93

Aká je definícia metriky Cena / výnosy?



Cena / výnosy (Price to sales ratio) ukazateľ predstavuje cenu spoločnosti v porovnaní s výškou jej tržieb.

The price to sales ratio, Price/Sales ratio, P/S ratio, or PSR, is a valuation metric for stocks. It is calculated by dividing the company's market cap by the revenue in the most recent year. It can also be calculated by dividing the per-share stock price by per-share revenue. The price to sales ratio is for trailing twelve months so the reported sales are for the four previous quarters. Longer time periods can be examined at times.

A smaller price to sales ratio is usually thought to be a better investment since the investor is paying less for each unit of sales. However, sales do not reveal the whole picture, as the company may be unprofitable with a low P/S ratio. Because of the limitations, this ratio is usually used only for unprofitable companies, since they don't have a price to earnings ratio (P/E ratio). The metric can be used to determine the value of a stock relative to its past performance. It may also be used to determine relative valuation of a sector or the market as a whole.

Price to sales ratios vary greatly between sectors, so they are most useful in comparing similar stocks within a sector or sub-sector. Comparing P/S ratios carries the implicit assumption that all firms in the comparison have an identical capital structure.

Cena / výnosy spoločností v sektore Health Care sektor na ASX v porovnaní so spoločnosťou Kazia Therapeutics

Čomu sa venuje spoločnosť Kazia Therapeutics?

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.

Firmy s metrikou cena / výnosy podobnou spoločnosti Kazia Therapeutics